AI & Machine Learning in Biotechnology
Drug development is booming in China. Should the U.S. view it as a threat or an opportunity?
If the U.S. wants to hold on to its title as the world’s top biotech innovator, it might want to take a page out of China’s book, a pioneer in CAR-T cell therapy said on Thursday.
“CAR-T cells were born in the U.S., actually here in New York City, but today there are more CAR-T cell trials in China than in the U.S.,” Michel Sadelain, director of the Columbia Initiative in Cell Engineering and Therapy, said at the STAT Breakthrough Summit East. “They’re variants on things that often have been published here before, but boom, the trial starts there and then they have patient data, while here we’re still thinking about how to find money to perform a trial.”
If the U.S. wants to hold on to its title as the world’s top biotech innovator, it might want to take a page out of China’s book, a pioneer in CAR-T cell therapy said on Thursday.
“CAR-T cells were born in the U.S., actually here in New York City, but today there are more CAR-T cell trials in China than in the U.S.,” Michel Sadelain, director of the Columbia Initiative in Cell Engineering and Therapy, said at the STAT Breakthrough Summit East. “They’re variants on things that often have been published here before, but boom, the trial starts there and then they have patient data, while here we’re still thinking about how to find money to perform a trial.”